News | October 08, 2008

Datascope Sponsors Clinical Trial of Intra-Aortic Balloon Counterpulsation in Patients With Acute MI

October 9, 2008 - Datascope Corp. said today it will sponsor a 300-patient, randomized clinical trial in high-risk acute myocardial infarction (MI) patients who are not in cardiogenic shock to show the efficacy of intra-aortic balloon counterpulsation in reducing infarct size.

Patients enrolled in the CRISP AMI trial will be randomized equally to usual care versus usual care plus intra-aortic balloon counterpulsation (IABC) therapy prior to percutaneous coronary intervention. The primary efficacy endpoint will be a 25 percent reduction in infarct size due to IABC utilization. The successful completion of this trial represents a worldwide opportunity of more than 200,000 patients, or $200 million per year, the company said.

By targeting at-risk patients in this study, the aim is to significantly reduce infarct size, thereby improving myocardial salvage. Infarct size is a well-established surrogate clinical marker for patient mortality, congestive heart failure and quality of life.

The basis for the trial is a 2007 animal study. This study concluded that left ventricular unloading with IABC therapy prior to reperfusion reduces the extent of myocardial damage. These data suggest that in high-risk ST elevation myocardial infarction (STEMI) patients, IABP afterload reduction prior to reperfusion might be more beneficial than IABP placement post perfusion. This study was published in the October 2008 issue of Catheterization and Cardiovascular Interventions.

The trial will be conducted at approximately 30 sites in the U.S., Europe and Australia.

IABC therapy is currently the gold standard for a variety of clinical indications. It is a Class I indication for cardiogenic shock in the ACC/AHA guidelines.

For more information:

Related Content

Sponsored Content | Videos | Cardiovascular Ultrasound| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
IABP recall for Maquet, Datascope intra-aortic balloon pump CS100 and CS300

The Datascope CS300 IABP console.

News | Hemodynamic Support Devices| June 20, 2017
June 20, 2017 — The U.S.
Abiomed Impella CP pVAD, third-generation CP
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — Abiomed Inc.
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp
Sponsored Content | Videos | Cardiovascular Ultrasound| May 26, 2017
This video, provided in partnership with the American Society of Echocardiography (ASE), is titled "Intraoperative Tr
Impella CP study to investigate door to left ventricular unloading time
News | May 09, 2017
May 9, 2017 — The first patient has been enrolled in the U.S.
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Technology | Intra-Aortic Balloon Pumps (IABP)| May 02, 2017
May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc.
Overlay Init